B6-hPDL1-V(2) Mouse

Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7H1), is an immune inhibitory receptor ligand. PD-L1 is a type I transmembrane protein with immunoglobulin V-like (IgV) and C-like (IgC) structural domains and is expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various types of tumor cells ^[1]. PD-L1 can bind to PD-1 on the surface of CD8+ T cells, inhibiting the activity of CD8+ T cells. This interaction can prevent the immune system from damaging normal tissues, but it can also be used by tumor cells to escape immune surveillance. Monoclonal antibodies that competitively bind to PD-L1 can relieve the immune function inhibition mediated by the binding of PD-1 and PD-L1. This can reactivate CD8+ T cells, triggering the human body's anti-tumor immune response ^[2]. Therefore, the development of antibody drugs targeting PD-1 and PD-L1 is a hot area in tumor immunotherapy.

This strain is a humanized model of the mouse Pdl1 gene in which the gene sequence encoding the extracellular domain (immunoglobulin V-like, IgV-like) of mouse PD-L1 protein is replaced with the corresponding human PD-L1 gene sequence. B6-hPDL1-V(2) mice can be used for the research of PD-L1 targeted drug development screening, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms ^[2-4]. It is important to note that B6-hPDL1-V(2) mice were engineered utilizing an identical genetic modification strategy as the B6-hPDL1-V strain (Catalog Number: C001420), with their sole distinction lying in their genetic background.